aluates Reports

$ 0.0

Automative

Wet Age-Related Macular Degeneration Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: November 2024

Report Code: QYRE-Auto-22D13064

Global Wet Age Related Macular Degeneration Treatment Market Research Report 2023

BUY CHAPTERS

Wet Age-Related Macular Degeneration Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-22D13064

Report

November 2024

Pages:97

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Novartis

Regeneron Pharmaceuticals

Bayer HealthCare

Kanghong Pharma

Wet Age-Related Macular Degeneration Treatment - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Wet Age-Related Macular Degeneration Treatment - Market

The most common treatment doctors use to slow vision loss from wet AMD is called anti-VEGF injections. These medicines help stop bleeding and leaking from blood vessels in the back of your eye. Most people with wet AMD will get anti-VEGF injections as their only treatment.

The global market for Wet Age-Related Macular Degeneration Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Wet Age-Related Macular Degeneration Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Wet Age-Related Macular Degeneration Treatment by region & country, by Type, and by Application.

The Wet Age-Related Macular Degeneration Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wet Age-Related Macular Degeneration Treatment.

Market Segmentation

Scope of Wet Age-Related Macular Degeneration Treatment - Market Report

Report Metric	Details
Report Name	Wet Age-Related Macular Degeneration Treatment - Market
CAGR	5%
Segment by Type:	Lucentis Eylea Avastin Others
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Novartis, Regeneron Pharmaceuticals, Bayer HealthCare, Kanghong Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Wet Age-Related Macular Degeneration Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Wet Age-Related Macular Degeneration Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Wet Age-Related Macular Degeneration Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Wet Age-Related Macular Degeneration Treatment - Market report?

Ans: The main players in the Wet Age-Related Macular Degeneration Treatment - Market are Roche, Novartis, Regeneron Pharmaceuticals, Bayer HealthCare, Kanghong Pharma

What are the Application segmentation covered in the Wet Age-Related Macular Degeneration Treatment - Market report?

Ans: The Applications covered in the Wet Age-Related Macular Degeneration Treatment - Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Wet Age-Related Macular Degeneration Treatment - Market report?

Ans: The Types covered in the Wet Age-Related Macular Degeneration Treatment - Market report are Lucentis, Eylea, Avastin, Others

1 Market Overview

1.1 Wet Age-Related Macular Degeneration Treatment Product Introduction

1.2 Global Wet Age-Related Macular Degeneration Treatment Market Size Forecast

1.2.1 Global Wet Age-Related Macular Degeneration Treatment Sales Value (2019-2030)

1.2.2 Global Wet Age-Related Macular Degeneration Treatment Sales Volume (2019-2030)

1.2.3 Global Wet Age-Related Macular Degeneration Treatment Sales Price (2019-2030)

1.3 Wet Age-Related Macular Degeneration Treatment Market Trends & Drivers

1.3.1 Wet Age-Related Macular Degeneration Treatment Industry Trends

1.3.2 Wet Age-Related Macular Degeneration Treatment Market Drivers & Opportunity

1.3.3 Wet Age-Related Macular Degeneration Treatment Market Challenges

1.3.4 Wet Age-Related Macular Degeneration Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Wet Age-Related Macular Degeneration Treatment Players Revenue Ranking (2023)

2.2 Global Wet Age-Related Macular Degeneration Treatment Revenue by Company (2019-2024)

2.3 Global Wet Age-Related Macular Degeneration Treatment Players Sales Volume Ranking (2023)

2.4 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Company Players (2019-2024)

2.5 Global Wet Age-Related Macular Degeneration Treatment Average Price by Company (2019-2024)

2.6 Key Manufacturers Wet Age-Related Macular Degeneration Treatment Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Wet Age-Related Macular Degeneration Treatment Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Wet Age-Related Macular Degeneration Treatment

2.9 Wet Age-Related Macular Degeneration Treatment Market Competitive Analysis

2.9.1 Wet Age-Related Macular Degeneration Treatment Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Wet Age-Related Macular Degeneration Treatment Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Age-Related Macular Degeneration Treatment as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Lucentis

3.1.2 Eylea

3.1.3 Avastin

3.1.4 Others

3.2 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Type

3.2.1 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Wet Age-Related Macular Degeneration Treatment Sales Value, by Type (2019-2030)

3.2.3 Global Wet Age-Related Macular Degeneration Treatment Sales Value, by Type (%) (2019-2030)

3.3 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Type

3.3.1 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Wet Age-Related Macular Degeneration Treatment Sales Volume, by Type (2019-2030)

3.3.3 Global Wet Age-Related Macular Degeneration Treatment Sales Volume, by Type (%) (2019-2030)

3.4 Global Wet Age-Related Macular Degeneration Treatment Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Other

4.2 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Application

4.2.1 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Wet Age-Related Macular Degeneration Treatment Sales Value, by Application (2019-2030)

4.2.3 Global Wet Age-Related Macular Degeneration Treatment Sales Value, by Application (%) (2019-2030)

4.3 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Application

4.3.1 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Wet Age-Related Macular Degeneration Treatment Sales Volume, by Application (2019-2030)

4.3.3 Global Wet Age-Related Macular Degeneration Treatment Sales Volume, by Application (%) (2019-2030)

4.4 Global Wet Age-Related Macular Degeneration Treatment Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region

5.1.1 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region (2019-2024)

5.1.3 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region (2025-2030)

5.1.4 Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region (%), (2019-2030)

5.2 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region

5.2.1 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region (2019-2024)

5.2.3 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region (2025-2030)

5.2.4 Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region (%), (2019-2030)

5.3 Global Wet Age-Related Macular Degeneration Treatment Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

5.4.2 North America Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

5.5.2 Europe Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

5.6.2 Asia Pacific Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

5.7.2 South America Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

5.8.2 Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Value

6.2.1 Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

6.2.2 Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

6.3.2 United States Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Wet Age-Related Macular Degeneration Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

6.4.2 Europe Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Wet Age-Related Macular Degeneration Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

6.5.2 China Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China Wet Age-Related Macular Degeneration Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

6.6.2 Japan Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Wet Age-Related Macular Degeneration Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

6.7.2 South Korea Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Wet Age-Related Macular Degeneration Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Wet Age-Related Macular Degeneration Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Wet Age-Related Macular Degeneration Treatment Sales Value, 2019-2030

6.9.2 India Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India Wet Age-Related Macular Degeneration Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Roche

7.1.1 Roche Company Information

7.1.2 Roche Introduction and Business Overview

7.1.3 Roche Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Roche Wet Age-Related Macular Degeneration Treatment Product Offerings

7.1.5 Roche Recent Development

7.2 Novartis

7.2.1 Novartis Company Information

7.2.2 Novartis Introduction and Business Overview

7.2.3 Novartis Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Novartis Wet Age-Related Macular Degeneration Treatment Product Offerings

7.2.5 Novartis Recent Development

7.3 Regeneron Pharmaceuticals

7.3.1 Regeneron Pharmaceuticals Company Information

7.3.2 Regeneron Pharmaceuticals Introduction and Business Overview

7.3.3 Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Product Offerings

7.3.5 Regeneron Pharmaceuticals Recent Development

7.4 Bayer HealthCare

7.4.1 Bayer HealthCare Company Information

7.4.2 Bayer HealthCare Introduction and Business Overview

7.4.3 Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Product Offerings

7.4.5 Bayer HealthCare Recent Development

7.5 Kanghong Pharma

7.5.1 Kanghong Pharma Company Information

7.5.2 Kanghong Pharma Introduction and Business Overview

7.5.3 Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Product Offerings

7.5.5 Kanghong Pharma Recent Development

8 Industry Chain Analysis

8.1 Wet Age-Related Macular Degeneration Treatment Industrial Chain

8.2 Wet Age-Related Macular Degeneration Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Wet Age-Related Macular Degeneration Treatment Sales Model

8.5.2 Sales Channel

8.5.3 Wet Age-Related Macular Degeneration Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Roche

Novartis

Regeneron Pharmaceuticals

Bayer HealthCare

Kanghong Pharma

List of Tables

Table 1. Wet Age-Related Macular Degeneration Treatment Market Trends

Table 2. Wet Age-Related Macular Degeneration Treatment Market Drivers & Opportunity

Table 3. Wet Age-Related Macular Degeneration Treatment Market Challenges

Table 4. Wet Age-Related Macular Degeneration Treatment Market Restraints

Table 5. Global Wet Age-Related Macular Degeneration Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Wet Age-Related Macular Degeneration Treatment Revenue Market Share by Company (2019-2024)

Table 7. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Wet Age-Related Macular Degeneration Treatment Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Wet Age-Related Macular Degeneration Treatment Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Wet Age-Related Macular Degeneration Treatment Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Wet Age-Related Macular Degeneration Treatment Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Wet Age-Related Macular Degeneration Treatment

Table 13. Global Wet Age-Related Macular Degeneration Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Age-Related Macular Degeneration Treatment as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Wet Age-Related Macular Degeneration Treatment Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Wet Age-Related Macular Degeneration Treatment Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Wet Age-Related Macular Degeneration Treatment Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Wet Age-Related Macular Degeneration Treatment Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Wet Age-Related Macular Degeneration Treatment Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region (2019-2024) & (%)

Table 44. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Region (2025-2030) & (%)

Table 45. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region (2019-2024) & (%)

Table 49. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Region (2025-2030) & (%)

Table 50. Global Wet Age-Related Macular Degeneration Treatment Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Wet Age-Related Macular Degeneration Treatment Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Volume, (2025-2030) & (K Units)

Table 57. Roche Company Information

Table 58. Roche Introduction and Business Overview

Table 59. Roche Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Roche Wet Age-Related Macular Degeneration Treatment Product Offerings

Table 61. Roche Recent Development

Table 62. Novartis Company Information

Table 63. Novartis Introduction and Business Overview

Table 64. Novartis Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. Novartis Wet Age-Related Macular Degeneration Treatment Product Offerings

Table 66. Novartis Recent Development

Table 67. Regeneron Pharmaceuticals Company Information

Table 68. Regeneron Pharmaceuticals Introduction and Business Overview

Table 69. Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Regeneron Pharmaceuticals Wet Age-Related Macular Degeneration Treatment Product Offerings

Table 71. Regeneron Pharmaceuticals Recent Development

Table 72. Bayer HealthCare Company Information

Table 73. Bayer HealthCare Introduction and Business Overview

Table 74. Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Bayer HealthCare Wet Age-Related Macular Degeneration Treatment Product Offerings

Table 76. Bayer HealthCare Recent Development

Table 77. Kanghong Pharma Company Information

Table 78. Kanghong Pharma Introduction and Business Overview

Table 79. Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Kanghong Pharma Wet Age-Related Macular Degeneration Treatment Product Offerings

Table 81. Kanghong Pharma Recent Development

Table 82. Key Raw Materials Lists

Table 83. Raw Materials Key Suppliers Lists

Table 84. Wet Age-Related Macular Degeneration Treatment Downstream Customers

Table 85. Wet Age-Related Macular Degeneration Treatment Distributors List

Table 86. Research Programs/Design for This Report

Table 87. Key Data Information from Secondary Sources

Table 88. Key Data Information from Primary Sources

List of Figures

Figure 1. Wet Age-Related Macular Degeneration Treatment Product Picture

Figure 2. Global Wet Age-Related Macular Degeneration Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Wet Age-Related Macular Degeneration Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Wet Age-Related Macular Degeneration Treatment Sales Volume (2019-2030) & (K Units)

Figure 5. Global Wet Age-Related Macular Degeneration Treatment Sales Price (2019-2030) & (US$/Unit)

Figure 6. Wet Age-Related Macular Degeneration Treatment Report Years Considered

Figure 7. Global Wet Age-Related Macular Degeneration Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Wet Age-Related Macular Degeneration Treatment Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Wet Age-Related Macular Degeneration Treatment Revenue in 2023

Figure 10. Wet Age-Related Macular Degeneration Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Lucentis Picture

Figure 12. Eylea Picture

Figure 13. Avastin Picture

Figure 14. Others Picture

Figure 15. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Wet Age-Related Macular Degeneration Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 17. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 18. Global Wet Age-Related Macular Degeneration Treatment Sales Volume Market Share by Type, 2023 & 2030

Figure 19. Global Wet Age-Related Macular Degeneration Treatment Price by Type (2019-2030) & (US$/Unit)

Figure 20. Product Picture of Hospital

Figure 21. Product Picture of Clinic

Figure 22. Product Picture of Other

Figure 23. Global Wet Age-Related Macular Degeneration Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 24. Global Wet Age-Related Macular Degeneration Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 25. Global Wet Age-Related Macular Degeneration Treatment Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 26. Global Wet Age-Related Macular Degeneration Treatment Sales Volume Market Share by Application, 2023 & 2030

Figure 27. Global Wet Age-Related Macular Degeneration Treatment Price by Application (2019-2030) & (US$/Unit)

Figure 28. North America Wet Age-Related Macular Degeneration Treatment Sales Value (2019-2030) & (US$ Million)

Figure 29. North America Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

Figure 30. Europe Wet Age-Related Macular Degeneration Treatment Sales Value (2019-2030) & (US$ Million)

Figure 31. Europe Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

Figure 32. Asia Pacific Wet Age-Related Macular Degeneration Treatment Sales Value (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

Figure 34. South America Wet Age-Related Macular Degeneration Treatment Sales Value (2019-2030) & (US$ Million)

Figure 35. South America Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

Figure 36. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Value (2019-2030) & (US$ Million)

Figure 37. Middle East & Africa Wet Age-Related Macular Degeneration Treatment Sales Value by Country (%), 2023 VS 2030

Figure 38. Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Value (%), (2019-2030)

Figure 39. Key Countries/Regions Wet Age-Related Macular Degeneration Treatment Sales Volume (%), (2019-2030)

Figure 40. United States Wet Age-Related Macular Degeneration Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 41. United States Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

Figure 42. United States Wet Age-Related Macular Degeneration Treatment Sales Value by Application (%), 2023 VS 2030

Figure 43. Europe Wet Age-Related Macular Degeneration Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 44. Europe Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

Figure 45. Europe Wet Age-Related Macular Degeneration Treatment Sales Value by Application (%), 2023 VS 2030

Figure 46. China Wet Age-Related Macular Degeneration Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 47. China Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

Figure 48. China Wet Age-Related Macular Degeneration Treatment Sales Value by Application (%), 2023 VS 2030

Figure 49. Japan Wet Age-Related Macular Degeneration Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 50. Japan Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

Figure 51. Japan Wet Age-Related Macular Degeneration Treatment Sales Value by Application (%), 2023 VS 2030

Figure 52. South Korea Wet Age-Related Macular Degeneration Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 53. South Korea Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

Figure 54. South Korea Wet Age-Related Macular Degeneration Treatment Sales Value by Application (%), 2023 VS 2030

Figure 55. Southeast Asia Wet Age-Related Macular Degeneration Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 56. Southeast Asia Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

Figure 57. Southeast Asia Wet Age-Related Macular Degeneration Treatment Sales Value by Application (%), 2023 VS 2030

Figure 58. India Wet Age-Related Macular Degeneration Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 59. India Wet Age-Related Macular Degeneration Treatment Sales Value by Type (%), 2023 VS 2030

Figure 60. India Wet Age-Related Macular Degeneration Treatment Sales Value by Application (%), 2023 VS 2030

Figure 61. Wet Age-Related Macular Degeneration Treatment Industrial Chain

Figure 62. Wet Age-Related Macular Degeneration Treatment Manufacturing Cost Structure

Figure 63. Channels of Distribution (Direct Sales, and Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions